Characteristics of adverse medication events in a children's hospital

Sonya Stacey1, Ian Coombes, Claire Wainwright

  • 1Queensland Children's Medical Research Institute, The University of Queensland, Brisbane, Queensland, Australia; School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia; Royal Children's Hospital, Children's Health Queensland Hospital and Health Service, Brisbane, Queensland, Australia.

Insights

International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) coding captured 85% of harm-related adverse medication events (AMEs) in children. Reviewing ICD-10 coded AMEs improves patient safety and quality of care.

Area of Science:

  • Pediatric Patient Safety
  • Medication Error Surveillance
  • Health Informatics

Background:

  • Adverse medication events (AMEs) in children pose significant risks to patient safety.
  • Accurate identification and reporting of AMEs are crucial for implementing effective safety measures.
  • Existing data sources for AME reporting may have varying levels of completeness and accuracy.

Purpose of the Study:

  • To compare the reporting of pediatric AMEs using International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) codes versus other data sources.
  • To assess the proportion of harm-related AMEs captured by ICD-10 coding.
  • To evaluate the documentation of AMEs in clinical alerts.

Main Methods:

  • Retrieved AME reports using ICD-10 codes (Y40-Y59, X40-X44) over a six-month period.
  • Manually reviewed patient charts to identify medication-related errors and harm during hospital admissions.
  • Collected data on medication details, error, harm, and alert documentation, and reviewed clinical incidents and pharmacist interventions.

Main Results:

  • ICD-10 coding identified 146 AMEs in 180 children, while other sources reported 117 incidents and 190 pharmacist interventions, totaling 447 events across all sources.
  • Of 158 harm-related events, ICD-10 coding captured 135 (85%), with minimal overlap between data sources.
  • Errors were noted in 3% of ICD-10 reports, 97% of incidents, and 100% of interventions; only 14% of ICD-10 harm events were documented in clinical alerts.

Conclusions:

  • ICD-10 coding is a valuable tool for documenting a substantial majority of harm-related AMEs in pediatric patients.
  • The findings highlight the potential of ICD-10 coded AME data to enhance patient safety initiatives.
  • Further integration and analysis of ICD-10 coded AME data can lead to improved quality of care in pediatric settings.
Abstract

Related Concept Videos

Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
116
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
400
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
547
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
954
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405